Leerink Partnrs Has Strong Forecast for HIMS FY2025 Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for Hims & Hers Health in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.49 per share for the year, up from their prior estimate of $0.39. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same period last year, the company earned ($0.04) earnings per share.

Several other research firms have also commented on HIMS. Bank of America raised their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Needham & Company LLC assumed coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial raised their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Finally, Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Stock Up 13.6 %

Hims & Hers Health stock opened at $23.44 on Thursday. The firm has a market cap of $5.03 billion, a price-to-earnings ratio of 53.27 and a beta of 1.06. Hims & Hers Health has a 52 week low of $6.58 and a 52 week high of $25.74. The business’s 50-day moving average price is $18.22 and its 200 day moving average price is $18.26.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the sale, the insider now owns 176,952 shares of the company’s stock, valued at approximately $2,919,708. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares of the company’s stock, valued at $362,342.55. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total transaction of $38,593.50. Following the completion of the sale, the insider now directly owns 176,952 shares of the company’s stock, valued at approximately $2,919,708. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 650,659 shares of company stock valued at $11,712,198. Corporate insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $111,000. Finally, Amalgamated Bank boosted its position in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.